Introduction
Intractable haematuria from the bladder can be lifethreatening and its management remains a dif®cult clinical problem. Severe bleeding can arise as a result of radiation cystitis, bladder carcinoma, cyclophosphamideinduced cystitis and severe infection. When irrigation of the bladder through a three-way catheter and fulguration of the bleeding lesions fail to stop the haematuria, a life-threatening situation can develop, when blood transfusion fails to keep pace with the rate of blood loss. Patients with massive uncontrollable haematuria are often elderly and un®t for cystectomy as a treatment. Many urologists have had to manage this dif®cult problem, and several different treatments have been attempted and described, with varying degrees of success. This aims of the review are to describe the methodology of different treatments so that the reader can readily reproduce a described method, and to review their ef®cacy and their morbidity.
Treatments for intractable haematuria ' Intravesical alum irrigation; ' Intravesical formalin; ' Hydrostatic pressure; ' Embolization; ' Hyperbaric oxygen for radiation cystitis; ' Sodium pentosanpolysulphate for chronic gross haematuria;
' Intravesical PG for cyclophosphamide-induced haematuria.
Whatever the method, the management of intractable haematuria begins with evacuation of all clots from the bladder before initiating any of the treatments listed. The evacuation can be by bladder irrigation through a largebore three-way catheter on the ward, or by cystoscopic bladder irrigation in the theatre.
Intravesical alum irrigation
Alum irrigation was ®rst introduced by Floyd Csir to Ostroff and Chenault [1] in 1982, who successfully treated six patients with massive bladder haemorrhage secondary to radiation cystitis, bladder carcinoma and haemorrhagic cystitis. The authors described continuous closed irrigation with a 1% alum solution in sterile water, through a large-bore three-way Foley catheter at the patient's bedside, with no general or regional anaesthesia. There were no reported side-effects, and no febrile or allergic reactions or a rise in serum creatinine level noted.
Alum (either aluminium ammonium sulphate or aluminium potassium sulphate) works by the astringent action of protein precipitation at the cell surface and super®cial interstitial spaces [1] . This leads to decreased capillary permeability, contraction of intercellular space, vasoconstriction, hardening of the capillary endothelium and a reduction in oedema, in¯ammation and exudate [2] .
The original paper by Ostroff and Chenault [1] described dissolving alum in sterile water to form a 1% solution. Kennedy et al. [3] prepared 1% solution of alum by dissolving 400 g of potash of alum (McCarthy's) in 4 L of hot sterile water; 300 mL of this stock solution was added to 3 L of sterile 0.9% sodium chloride through a sterilizing ®lter, to form the irrigating alum solution. The clots in the bladder were washed out by a 26 F whistle-tipped catheter under local anaesthesia, and this was replaced with a 22 F three-way catheter. The bladder was irrigated with up to 30 L of the solution of alum in 24 h. Using the alum solution described above, Kennedy et al. [3] treated eight patients, all except one of whom had previously received radiotherapy for bladder carcinoma and had not responded to diathermy of bleeding points; one had also undergone formalin instillation, balloon distension and selective arterial embolization. All patients stopped bleeding within 4 days of being irrigated with alum solution and tolerated it well. Two patients experienced suprapubic discomfort, two had low-grade pyrexia (<38uC) and two developed ileus. Serum aluminium levels were measured in four patients and one who was asymptomatic had a high level (1.8 mmol/L, normal up to 1.0 mmol/L). A colloid-like precipitation occurred with slow irrigation, which occasionally blocked the catheter and could be avoided by increasing the¯ow rate.
Goel et al. [4] reported good results with continuous irrigation of 1% alum solution (50 g of potassium aluminium sulphate in 5 L of water) at a rate of 5 mL/ min in nine patients in whom massive bladder haemorrhage persisted despite evacuation of clots and normal saline irrigation for at least 24 h. Haematuria ceased in all patients and biopsy of the tumour and normal--appearing bladder mucosa showed no alteration in histological characteristics. There was no delayed urgency or frequency of micturition, and no urethritis or stricture formation at the 6-month follow-up.
In another study [2] , 15 patients with massive haematuria were treated with a 1% aluminium potassium sulphate solution in sterile distilled water; 10 patients had a complete response, two a partial response (in whom blood transfusion was no longer needed) and the treatment failed in three. In this group, 13 patients had bladder tumours, one had radiation cystitis and one had undergone TURP. There were no side-effects in six patients, but side-effects comprising mainly suprapubic pain and spasms occurred in seven, which were controllable with antispasmodic medication. Two patients with small bladders did not tolerate the procedure and treatment had to be abandoned. There were no cases of aluminium intoxication or vesical retraction, and no VUR apparent on radiological imaging.
A 1% solution of alum in sterile water has a concentration of 1.05 g/L and a pH of 4.5, which could account for the side-effects of suprapubic pain and spasms [2] . The toxicity of the aluminium is determined by its pharmacokinetic properties of absorption and excretion. It is excreted by the kidney, with a potential excretion reserve of up to 30 times normal values [5] . Pathological accumulation may occur as a result of renal insuf®ciency, massive absorption or accumulative absorption. The toxicity of aluminium causes neuro®brillary degeneration in the CNS which manifests as encephalopathy, malaise, speech disorder, dementia, convulsions and vomiting. Kavoussi et al. [6] reported a 74-year-old man with renal impairment (serum creatinine 177 mmol/L), and normal electrolyte levels and coagulation studies, who underwent a 1% alum irrigation consisting of 270 g of alum in 36 h. Gross haematuria was controlled but he became progressively lethargic, confused and developed nonfocal seizures. His serum aluminium level was 17 ng/L (no toxic at <10 mmol/L). He developed metabolic acidosis, hyponatraemia and worsening renal function, with a serum creatinine level of 513 mmol/L. After percutaneous nephrostomy and conservative management, the serum creatinine and aluminium levels returned to normal, and the patient made a full recovery. A death was reported in an elderly man with severe renal impairment (serum creatinine 420 mmol/L) who was treated with 1% alum irrigation and received a total of 9.6 L in 48 h. The bleeding was stopped but he became lethargic, suffered respiratory depression and died 4 days after hospitalization. His serum aluminium levels on 3 successive days beginning on the day of irrigation showed rising levels of 3066, 4560 and 7014 nmol/L (toxic when >2000) but these results were not available until the ®fth day. His large bladder tumour may have contributed to a large absorptive surface area, the absorption not being adequately excreted because of renal failure. In contrast, Modi and Paterson [7] reported a patient with severe renal failure (serum creatinine 1520 mmol/L) and haematuria secondary to bladder amyloidosis who responded completely to intravesical alum irrigation at the full dose (1% solution at 250 mL/hour for 72 h or 18 L) with no evidence of metabolic acidosis or elevated aluminium levels. Apart from aluminium toxicity, aluminium salts are known to cause a severe allergic reaction in susceptible individuals after topical use, and caution must be exercised in patients with a history of allergic diathesis [8] .
In summary, intravesical 1% alum irrigation for intractable haematuria is generally safe, effective and well tolerated. The patient can be irrigated at low cost with no regional or general anaesthesia, open surgery or elaborate radiological procedures; the procedure does not distort the local tissue histology. Aluminium toxicity may occur in patients with renal impairment and large absorptive surfaces, and the development of lethargy, confusion, seizures, metabolic acidosis or elevated aluminium concentration mandates cessation of treatment.
Protocols for alum irrigation:
' Using a 1% alum solution; 50 g of alum is dissolved in 5 L sterile water and used to irrigate the bladder at 250±300 mL/h; 
Intravesical Helmstein's hydrostatic pressure
Helmstein [9] ®rst introduced hydrostatic pressure therapy in 1966 for the treatment of bladder cancer. He reported on 35 patients and found total necrosis of the tumour in 27. In 1973 he published a paper on the use of this treatment in controlling haematuria; he reported on six patients, achieving lasting haemostasis in three, temporary haemostasis in two and no effect in one.
Helmstein's original treatment involved giving a high epidural anaesthetic to achieve total atony of the bladder (in only one study [10] was general anaesthesia used and the authors claimed a decreased risk of bladder rupture). The intravesical pressure was increased by either simply ®lling the bladder with normal saline via a Foley catheter, or by using a balloon attached to a cut Foley catheter through which a steel tube was advanced (both condoms [11] , party balloons [12] and specially designed balloons [13] have been used). The commoner approach was to distend the bladder with a balloon rather than to ®ll the bladder with normal saline. The balloon was then ®lled and the pressure measured by either measuring the distance between the symphysis pubis and the giving set [1, 14] or by a transducer attached to the Foley catheter [13] .
The pressure to which the balloon was in¯ated had been varied; Helmstein [1] used a pressure equivalent to the systolic blood pressure and claimed that pressures below this did not achieve haemostasis. However, other authors [11, 12] have used a pressure of 10±20 cmH 2 O above diastolic with no loss of ef®cacy and a decreased risk of bladder rupture. The pressure was maintained for 6±7 h under epidural anaesthesia. Helmstein then gave mannitol after the procedure because of the potential effect of prolonged obstruction of the ureteric ori®ces, but it has been shown to have no effect on renal function [11] .
Intravesical hydrostatic treatment is believed to work by a simple tamponade mechanism [9] ; there is a linear relationship between bladder blood¯ow and bladder pressure [15] , i.e. the higher the intravesical pressure the less the blood¯ow.
England et al.
[16] evaluated Helmstein's method for the treatment of bladder carcinoma in a study of 49 patients; in nine patients whose major problem was uncontrollable bleeding (six from tumour and three from post-radiation necrosis) all were controlled immediately. Those who bled from post-radiation cystitis did not have recurrent bleeding and in those who bled from tumour, two had no further bleeding at 6 months, two had successful further distensions at 6 and 8 months, one underwent cystectomy at 4 months and one died at 4 months with no recurrence. The authors therefore concluded that hydrodistension to control bleeding might have an important role. Hammonds et al. [12] hydrodistended the bladder to a pressure of 115±145 cmH 2 O for 6 h in eight patients in whom conservative management of their haematuria had failed. Eight of nine treatments were successful (one patient being treated twice). Severe bleeding recurred in two patients within a follow-up of 2±7 months; one was treated by transurethral resection of the recurrent tumour and the other was successfully controlled by further bladder hydrodistension. The device used was similar to that described by Helmstein [1] . The tip of a round-ended 18 F Foley catheter was excised and placed within an ordinary rubber party-type balloon or a condom. The balloon or condom was tied to the distal end of the catheter so that the Foley balloon could be in¯ated within it. The device was sterilized by immersion in 1 : 2000 aqueous chlorhexidine solution for 30 min. A curved introducer was placed through the catheter to stretch the balloon, with its tip covered by the loose, cut distal end of the catheter to prevent perforating the balloon. This was then introduced into the bladder along the urethra. The Foley balloon was in¯ated with sterile water and pulled back to the bladder neck to con®rm its position within the bladder. The balloon was gradually distended with sterile saline from a central venous pressure-monitoring set, through which the balloon pressure relative to the pubic symphysis could be monitored. The ®nal pressure was adjusted to exceed the patient's diastolic blood pressure by 25 cmH 2 O, an amount lost in overcoming the elasticity of the balloon. After 6 h, the balloon was removed and a three-way catheter inserted for bladder irrigation until the urine became clear of blood.
Iversen Hansen et al. [11] not only examined the effect of hydrodistension therapy on haematuria, ®nding that six of 12 patients had no further episodes at 10 months, but also assessed the effect it had on bladder and renal function, using urodynamics and creatinine as measures. There were no detectable changes in voiding pattern and renal function was unchanged after treatment.
The most common serious side-effect of hydrodistension was rupture of the bladder, which could be either partial or total. In his ®rst 13 treatments, Helmstein described two total ruptures and one perforation through an ulcerated tumour; others have reported ruptured bladder [10, 16] . The occurrence of perforation could be predicted by a sudden increase in the drip-rate of the infused normal saline. Patients with a ruptured bladder in these series were managed conservatively and successfully with urethral catheterization.
Deaths after the procedure have been reported but not directly attributed to the treatment. An elderly patient in heart failure had an extension of a recent myocardial infarction [16] and another two patients died from THE MANAGEMENT OF INTRACTABLE HAEMATURIA 953 pulmonary embolism within 3 days of the procedure [10] . The most common minor complications included nausea and vomiting, temporary incontinence [12] , severe abdominal pain that settled spontaneously [14] and pyrexia [10, 12, 14] .
In summary, Helmstein's hydrodistension therapy is effective for treating severe bleeding from the bladder but seems to have only a temporary effect. However, it has a relatively low morbidity, which makes it ideal for multiple uses and for those patients unable to undergo a general anaesthetic.
The protocol for hydrodistension therapy:
' Use epidural anaesthesia; ' Use a Foley catheter and balloon or condom (as described);
' Fill the balloon or condom to 10±25 cmH 2 O above diastolic BP for 6 h.
Intravesical formalin solutions
Intravesical formalin was ®rst described by Brown [17] in 1969 as a method of controlling intravesical haemorrhage in patients with advanced carcinoma of the bladder. He used a 10% formalin solution (37.8% formaldehyde) and achieved a success rate of >90%.
Since then, further experiences has been reported by several authors who have alerted noted its potential side-effects and complications. Intravesical formalin has been used to treat severe haematuria caused by primary or secondary bladder carcinoma, and cystitis secondary to radiation or cyclophosphamide treatment [18] . Formalin is used as a preservative, tissue ®xative, disinfectant and embalming agent, and is widely used in industry. Locally in the bladder, formalin precipitates cellular proteins of the bladder mucosa [19] , and has occluding and ®xative actions on telangiectatic tissue and on small capillaries [20] . Changes involve oedema, in¯ammation and necrosis throughout all layers of the bladder [21] . When formalin is absorbed into the systemic circulation it is converted into formic acid and formate; there is no free formaldehyde in serum. Formic acid triggers an inhibition of cholinesterase, succinate oxidation, anaerobic glycolysis and hexokinase [22] . Toxic levels of formic acid are reportedly 0.8 g/L in blood and 0.66 g/L in urine.
Formalin is instilled under general or spinal anaesthesia. There is wide variation in the concentration and volume of formalin solution used, the contact time, technique and type of follow-up irrigation (saline, distilled water, alcohol and saline, alcohol only and no irrigation) after formalin instillation. Among the different therapeutic variables used the concentration of formalin remains the most important, as the complication rate increases with increasing concentration.
Formaldehyde in its natural state is a gas and the maximum concentration in solution is 37%; a 100% solution of formalin is equivalent to a 37% solution of formaldehyde. The concentration must be de®ned, as some pharmacies refer to a 10% dilution of formaldehyde as 10%, while others refer to it as 3.7%; 10% formalin was used in earlier studies, except those by Shah and Albert [19] and Spiro et al. [23] , who used 4% formalin. Fair [24] used 10% formalin in his ®rst four patients and 1% formalin in his last 14. Others have used a formalin concentration of 3±10% [25] , 4±10% [26] and 5±10% [27] . Fair reported a 75% complication rate when using 10% formalin and no signi®cant complications when only a 1±2% solution was used. Godec and Gleich [25] reported that the use of a low formalin concentration (<4%) was associated with complications in one of ®ve reports reviewed, whereas a 10% formalin solution was associated with complications in 13 of 19 articles reviewed.
The volume of formalin instilled was 10±300 mL, or up to bladder capacity; the contact time was 3±30 min, attained by clamping the catheter or holding the catheter above the level of the pubic ramus with no clamping. These variables correlated less well with the complication rate. Instead of holding a ®xed volume of formalin solution in the bladder, with the risk of ureteric re¯ux in the event of detrusor contraction, Fair [24] irrigated the bladder with a 1% formalin solution for 10 min, and reported no complications.
Formalin is an effective tool for controlling severe haematuria but serious complications may be encountered, and these potential complications should be known to the urologist when this treatment is contemplated. The complications of intravesical formalin include a small contracted bladder, urinary incontinence, VUR, ureteric strictures, vesico-ureteric junction obstruction with hydroureteronephrosis, acute tubular necrosis with anuria, vesicovaginal ®stula, vesico-ileal ®stula, a toxic effect on myocardium, and rupture of the bladder [23,25,26,28±33] . Fibrosis of the bladder, with reduced capacity and increased urinary frequency, is a common clinical sequel. Hydronephrosis and re¯ux are a consequence of the narrowing and rigidity of the ureteric ori®ces, and subsequent instillations may be associated with re¯ux of formalin into the kidneys. It seems likely that formalin might trigger bladder spasms in the neurologically intact bladder, through sensory stimulation of the bladder mucosa. Bilateral ureterohydronephrosis may be attributed to obstruction of the vesicoureteric junctions by the ®xative effect of formalin [23] . Five deaths have been reported [26,28,33±35] ; the minimal lethal dose when ingested is 30 mg of 40% formalin solution [36] , which equates to 120 mg of 10% formalin.
Intravesical formalin is effective in controlling massive haematuria, with success rates reported to be 80% [18] , 83% [19] and 92% [17] , while others have reported bene®ts in all patients [24, 37, 38] . However, because of the potential serious complications, it should be used with great caution and only after more conservative measures have failed. The use of a high concentration of formalin (e.g. 10%) in patients with a long lifeexpectancy may lead to permanent damage and result in the loss of a functioning bladder.
The protocol for intravesical formalin instillation:
' A low initial formalin concentration (1±2%) should be used, with progressively higher concentrations if necessary.
' Use cystography to exclude re¯ux; protect with a Fogarty catheter in the presence of re¯ux.
' Use spinal or general anaesthesia. ' Evacuate blood clots and coagulate major bleeding vessels.
' Protect all external areas on the skin and mucosa with Vaseline; pack the vagina to prevent leakage from catheter.
' Irrigate the bladder with a low concentration (1±2%) of formalin for 10 min under gravity at <15 cmH 2 O, or instil formalin under gravity at <15 cmH 2 O and leave the catheter open at a level just above the pubic ramus.
' Monitor the bladder pressure if possible and discontinue the procedure when the pressure is >50 cmH 2 O.
' Limit the contact time to 15 min.
Embolization
Therapeutic embolization for the control of bladder haemorrhage was ®rst reported in 1974 by Hald and Mygiand [39] , who used muscle fragments to occlude one internal iliac artery in a patient with severe bleeding from irradiation cystitis. The procedure has the advantage of being possible under local anaesthesia and a review of published studies showed the successful control of severe haematuria in 32 of 35 patients (92%) [40] . The internal iliac artery on one or both sides may be catheterized from the ipsilateral or contralateral femoral artery, or from the left axillary artery. The axillary artery can be dif®cult to puncture and may pose a dif®cult surgical problem if damaged or thrombosed; however, it offers an attractive approach to the pelvic vessels, as it is relatively easy to steer a catheter into both internal iliac arteries and into their main branches from the same puncture site. The risk of arterial damage is very low if a thin catheter (e.g. 7 F) is used and if the patient's arm is elevated in a sling for 12 h after the procedure [40] .
Therapeutic embolization has been achieved by completely occluding the internal iliac artery with blood clot [41] , Tachotop @ [42] , Gelfoam @ (gelatine sponge, Pharmacia and Upjohn, Sweden) [43, 44] , Histoacryl @ (Aesculap AG, Tuttlingen, Germany) [45] or isobutyl-2-cyanoacrylate [43, 44] . A more selective approach was to identify the bleeding points and selectively catheterize the anterior division of the appropriate internal iliac artery, embolizing with a gelatine sponge [46] . An even more selective approach was to embolize the superior and inferior vesical arteries with Gelfoam on one side, after catheterizing from the ipsilateral femoral artery [47] . Using a coaxial catheter technique with 0.64 mm and 0.89 mm coils (2.5 or 5 cm long), superselective embolization occludes speci®c regions supplied by very small vessels and may reduce the complication rates [48] .
The commonest complication of therapeutic embolization of the internal iliac arteries is gluteal pain, which can be very severe if the superior gluteal artery is completely occluded by embolic material. Distal embolization of the lower limb arteries caused by re¯ux of emboli into the aorta is a well recognized complication of Gelfoam embolization [49] . Gangrene of the bladder has been reported after embolization of one internal iliac artery [50, 51] . A rare but serious complication is a neurological defect affecting one or both lower limbs after embolizing the internal iliac arteries with Tachotop [42] and isobutyl-2-cyanoacrylate [44] . Two theories have been proposed for this complication; one suggests that small emboli pass from the superior gluteal artery into spinal arteries via collateral vessels between the superior gluteal, lumbar and spinal arteries [44] ; the other that embolizing the companion artery of the sciatic nerve (arteria comitans nervi ischiadici), which arises from the anterior division of the internal iliac artery, leads to temporary or permanent ischaemic damage to the nerve [40] .
Hyperbaric oxygen therapy for haemorrhagic radiation cystitis
Irradiation of the bladder causes a progressive obliterative endarteritis of the small blood vessels, resulting in cellular hypoxia [52] . The rationale of hyperbaric oxygen treatment is to reverse the vascular radiation-induced pathophysiology [53, 54] by causing neovascularization of the bladder wall and so increase tissue oxygen tension. Since it was ®rst described in the 1980s, more than 90 cases have been reported [55±61] . In a prospective study of 40 patients with biopsy-con®rmed radiation cystitis and severe haematuria, 30 (75%) had no haematuria for at least 3 months after hyperbaric oxygen therapy; seven patients (17%) had occasional slight haematuria and three (7.5%) did not respond to the treatment [55] . In that study, haematuria resolved completely or improved in 37 patients (93%) and the recurrence rate was 0.12%/ year, with no adverse effects. The bladder was preserved (cystectomy avoided) in 36 patients (90%). Cystoscopy after hyperbaric oxygen therapy showed a decrease in haemorrhagic sites and telangiectasias [62] . Hyperbaric oxygen therapy did not promote cancer growth [63] and a review of published reports concluded similarly that there was no evidence of tumour growth enhancement [64] . Potential side-effects caused by barometric pressure changes or toxicity may be associated with hyperbaric oxygen treatment, but serious complications such as CNS toxicity and decompression sickness are clinically rare in such low-pressure and brief oxygen-inhalation treatments [65, 66] .
The protocol for hyperbaric oxygen therapy:
' Twenty sessions of 100% oxygen inhalation at 0.3 MPa in a multiplace hyperbaric chamber (90 min/session);
' Daily sessions ®ve or six times a week; the number of sessions may be increased to 40.
There are 25 registered hyperbaric oxygen centres in the UK; the contact address is the British Hyperbaric Association (current chairman Dr A. P. Colvin), North Sea Medical Centre, Lowestoft Rd, Gorleston, Great Yarmouth NR 31 6SG, UK (Tel.: 01493±414141).
Oral sodium pentosanpolysulphate
Oral sodium pentosanpolysulphate was successful in controlling chronic gross haematuria secondary to pelvic irradiation in ®ve patients who failed conservative attempts (including cystoscopy) to control bleeding [67] . The therapy consisted of 100 mg of oral sodium pentosanpolysulphate three times per day; the average time to control bleeding was 4±7 weeks of therapy.
Precisely how sodium pentosanpolysulphate controls haematuria is unknown, but is postulated to increase the natural defence of the bladder-urine interface by coating the lining of the bladder, which may have been damaged by irradiation. Oral sodium pentosanpolysulphate has no detectable anticoagulant activity, is safe and not toxic [67] .
Intravesical PGs for cyclophosphamide-induced haemorrhagic cystitis
Haemorrhagic cystitis is a well known complication after cyclophosphamide therapy with an incidence of 2±40% [68] . Cyclophosphamide, an oxazaphosphorine alkylating agent, is used in the treatment of B cell malignant diseases and some solid tumours, conditioning before bone marrow transplantation and in the treatment of certain benign conditions, e.g. nephrotic syndrome, rheumatoid arthritis and systemic lupus erythematosus. Cyclophosphamide results in acrolein (a hepatic metabolite) being excreted in the urine, and this causes haemorrhage, oedema, ulceration and necrosis of the urothelium [69, 70] .
PGE1, -E2 and -F2a _ [71±75] have been used to treat haemorrhagic cystitis secondary to cyclophosphamide administration. The precise mechanism of its action is unknown but is postulated to provide a cytoprotective function, possibly by regulating a mucous barrier [76, 77] , encourage platelet aggregation, induce vasoconstriction and cause smooth muscle contractions in mucosal and submucosal blood vessels [78] .
Levine and Jarrard [78] reviewed their experience with 18 consecutive patients who received intravesical carboprost tromethamine (a commercially available PGF2a) for severe haemorrhagic cystitis after cyclophosphamide chemotherapy. The intravesical PG therapy was initiated only after forced diuresis and continuous saline bladder irrigation were unsuccessful in controlling the bleeding, and only after blood transfusion of >1 unit/day was required. The patients underwent cystoscopy and clot evacuation, and received an intravesical instillation of carboprost tromethamine by two different protocols; the ®rst with 4±10 mg/L of carboprost tromethamine for 2 h four times per day, alternating with continuous saline bladder irrigation for 2 h; the second by continuous saline bladder irrigation with 8±10 mg/L carboprost tromethamine. The gross haematuria completely resolved in half of the patients in each treatment protocol group. The median (range) period of treatment required to achieve a complete response was 6 (2±7) days. Bladder spasm occurred in 14 of the 18 patients but there were no changes in renal or other bladder function, or any systemic complications.
The advantages of intravesical PGs for treating cyclophosphamide-induced haemorrhagic cystitis include good tolerance with no signi®cant toxicity or anaesthetic requirement, bedside administration, no signi®cant complication in patients with VUR and no precipitate to block catheters. The disadvantages include a high percentage of bladder spasms, intensive nursing supervision, the cost, and failure to control bleeding in all patients.
The protocols for intravesical PGs:
Protocol 1
' Cystoscopy, clot evacuation and placement of a threeway 24 F Foley catheter.
' Instil 50 mL of 4±8 mg/L carboprost tromethamine in the bladder and maintain for 1 h.
' Drain the bladder, instil another 50 mL and maintain for 1 h.
' Unclamp the catheter and irrigate the bladder with normal saline.
' Repeat the carboprost tromethamine instillation four times a day.
' Each 24 h course consists of a total of 400 mL carboprost tromethamine for 8 h.
' If there is no improvement by courses 4±6, the dosage is increased to 10 mg/L.
Protocol 2
' Irrigate the bladder continuously with 8±10 mg/L carboprost tromethamine at 100 mL/h for 10 h.
Conclusion
There are various treatment options for intractable haematuria arising from several conditions applicable when more conservative measures have failed and before major surgery is contemplated or deemed unsuitable. The decision to use a particular treatment depends on the ®tness of the patient and the anaesthetic requirement, the severity of the haematuria, the treatments available, the risks and severity of complications, and the prognosis of the condition. Intravesical formalin is effective in controlling intractable haematuria, but because it has potential serious complications it should be used with great caution and only after more conservative measures have failed. Its use requires spinal or general anaesthesia and it should not be used in patients with a long lifeexpectancy, as it may lead to permanent damage and result in the loss of a functioning bladder. In contrast, intravesical 1% alum irrigation for intractable haematuria can be used with no spinal or general anaesthesia or elaborate radiological procedures, is generally safe, effective and well tolerated, and is suitable as a ®rst-line treatment. Hydrodistension of the bladder must be conducted under epidural anaesthesia but is otherwise generally safe and effective, although the effect may not be prolonged. Embolization can be used with local anaesthesia, but it depends on the expertise available and the acceptability by the physicians and patients of the potential serious complications. Hyperbaric oxygen therapy for haemorrhagic radiation cystitis is safe and effective but is not widely available, and it may be cumbersome to transport sick patients undergoing bladder irrigation to a specialist facility housing the hyperbaric chamber. Table 1 lists the types of treatment available for intractable haematuria and their comparative anaesthetic requirements, response rates, ease of availability, complications and reported deaths. 
